DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Clinical trials for DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive drug targets brain tumors in early trial
Disease control Recruiting nowThis early-phase study tests a radioactive drug called 177Lu-PSMA-617 combined with standard chemotherapy (temozolomide) for people with aggressive IDH wild type gliomas. The goal is to see if the combination is safe and to get a first look at whether it helps control tumor growt…
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for kids with aggressive brain cancer: targeted drug combo trial launches
Disease control Recruiting nowThis study tests whether adding two different drug combinations after radiation can help children and young adults (up to age 21) with high-grade gliomas, including DIPG, live longer. One group receives ribociclib plus everolimus; another gets ribociclib plus temozolomide. The go…
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail takes on deadly brain cancer
Disease control Recruiting nowThis trial is testing two experimental drugs, avutometinib and defactinib, alone or with a standard chemotherapy (temozolomide), in people with high-grade malignant brain tumours like glioblastoma. The study aims to find a safe dose and see if the drugs can shrink tumours or stop…
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC